Patient-selected treatment partners did not protect against drug resistance during first-line NNRTI-based HAART in a randomized trial.
Taiwo
Babafemi O
BO
Idoko
John A
JA
Marcelin
Anne-Geneviève
AG
Otoh
Ihedinachi
I
Reddy
Susheel
S
Iyaji
Paul G
PG
Agbaji
Oche
O
Penugonda
Sudhir
S
Agaba
Patricia A
PA
Murphy
Robert L
RL
D019943:Amino Acid Substitution / Q000235:genetics; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D020125:Mutation, Missense; D009549:Nigeria
D019380:Anti-HIV Agents; C514824:reverse transcriptase, Human immunodeficiency virus 1; D054303:HIV Reverse Transcriptase